Clinical evaluation of efficacy and safety of α-keto analogs of essential amino acids supplementation in patients of chronic kidney disease

Irfan A. Khan, Mohammad Nasiruddin, Shahzad F. Haque, Rahat A. Khan


Background: The objective was to evaluate the efficacy and safety of α-keto analogs of essential amino acids (KAA) as a supplement in chronic kidney disease (CKD).

Methods: A prospective comparative study was conducted in patients of CKD of a tertiary care center of North India. Patients were randomly divided into two interventional groups. Group I (control) was advised conservative management and placebo while Group II (KAA) given conservative management along with KAA (600 mg, thrice daily) for 12 weeks. Hemogram, renal function tests, lipid profiles were done, and adverse effects were recorded at 0, 4, 8, and 12 weeks of treatment.

Results: There was progressive improvement in clinical features in both groups after 12 weeks of treatment, but KAA group showed more marked improvement as compared with the control group. Both groups showed gradual improvement in the biochemical parameters as compared to their pre-treated values, which was more marked in KAA supplemented group. There was a reduction in blood glucose, blood urea, serum creatinine, and 24 h total urine protein. There was an increase in hemoglobin, 24 h total urine volume and glomerular filtration rate. KAA group showed significant (p<0.05) improvement in lipid profiles as compared with the control group. There was no statistical difference in two groups with respect to side-effects (p>0.05).

Conclusion: KAA supplementation along with conservative management is efficacious and safe in preventing the progression of disease in patients of CKD.


Keto amino acids, Glomerular filtration rate, Conservative management, End stage renal disease

Full Text:



Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int. 2007;72(3):247-59.

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 2 Suppl 1:S1-266.

Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, et al. Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2013;14:114.

Sakhuja V, Sud K. End-stage renal disease in India and Pakistan: burden of disease and management issues. Kidney Int Suppl. 2003;(83):S115-8.

Chang JH, Kim DK, Park JT, Kang EW, Yoo TH, Kim BS, et al. Influence of ketoanalogs supplementation on the progression in chronic kidney disease patients who had training on low-protein diet. Nephrology (Carlton). 2009;14(8):750-7.

Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay end-stage renal disease in non diabetic adults with chronic renal failure. Cochrane Database Syst Rev. 2000;(2):CD001892.

Haque SF, Ansari AP. Keto-analogues of essential amino acids improves the clinical outcome in patients with CKD. J Med Sci Res. 2011;2(2):64-6.

Teplan V. Supplements of keto acids in patients with chronic renal failure. Nefrol Derg. 2004;13(1):3-7.

Aparicio M, Gin H, Potaux L, Bouchet JL, Morel D, Aubertin J. Effect of a ketoacid diet on glucose tolerance and tissue insulin sensitivity. Kidney Int Suppl. 1989;27:S231-5.

Chen JB, Cheng BC, Kao TW. A comparison of progression of chronic renal failure: low dose vs standard dose ketoacids. Kidney Res Clin Pract. 2012;31(2):A24.

Walser M, Coulter AW, Dighe S, Crantz FR. The effect of keto-analogues of essential amino acids in severe chronic uremia. J Clin Invest. 1973;52(3):678-90.

Mitch WE, Abras E, Walser M. Long-term effects of a new ketoacid-amino acid supplement in patients with chronic renal failure. Kidney Int. 1982;22(1):48-53.

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 2 Suppl 1:S1-266.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229-32.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.

Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004;18(2):73-8.

Kher V. End-stage renal disease in developing countries. Kidney Int. 2002;62(1):350-62.

Richards P, Metcalfe-Gibson A, Ward EE, Wrong O, Houghton BJ. Utilisation of ammonia nitrogen for protein synthesis in man, and the effect of protein restriction and uraemia. Lancet. 1967;2(7521):845-9.

Ell S, Fynn M, Richards P, Halliday D. Metabolic studies with keto acid diets. Am J Clin Nutr. 1978;31(10):1776-83.

Chen N, Jin Y, Ren H, Jing X, Shen P, Huang X. Anti-inflammatory effects of low protein diet supplemented with keto-amino acid in the treatment of type 2 diabetic nephropathy. Kidney Res Clin Pract. 2012;31(2):A24.

Di Iorio BR, Minutolo R, De Nicola L, Bellizzi V, Catapano F, Iodice C, et al. Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney Int. 2003;64(5):1822-8.

Bellizzi V, Di Iorio BR, De Nicola L, Minutolo R, Zamboli P, Trucillo P, et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int. 2007;71(3):245-51.

Di Iorio B, Di Micco L, Torraca S, Sirico ML, Russo L, Pota A, et al. Acute effects of very-low-protein diet on FGF23 levels: a randomized study. Clin J Am Soc Nephrol. 2012;7(4):581-7.

Di Iorio BR, Bellizzi V, Bellasi A, Torraca S, D’Arrigo G, Tripepi G, et al. Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients. Nephrol Dial Transplant. 2013;28(3):632-40.

Marzocco S, Dal Piaz F, Di Micco L, Torraca S, Sirico ML, Tartaglia D, et al. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Blood Purif. 2013;35(1-3):196-201.

Garneata L, Mircescu G. Effect of low-protein diet supplemented with keto acids on progression of chronic kidney disease. J Ren Nutr. 2013;23(3):210-3.

Aparicio M, Cano NJ, Cupisti A, Ecder T, Fouque D, Garneata L, et al. Keto-acid therapy in predialysis chronic kidney disease patients: consensus statements. J Ren Nutr. 2009;19 5 Suppl: S33-5.